Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Plasma cell 7Other hematologic neoplasm 5CNS 1

Conditions

Brain Neoplasms 1702Glioblastoma 1308Glioma 995Neuroblastoma 408Central Nervous System Neoplasms 384Astrocytoma 384Gliosarcoma 286Oligodendroglioma 238Neoplasms 226Breast Neoplasms 216Meningioma 179Medulloblastoma 172Carcinoma, Non-Small-Cell Lung 149Recurrence 147Neoplasm Metastasis 138Lung Neoplasms 138Ependymoma 128Melanoma 119Sarcoma 117Neurofibromatosis 1 110Meningeal Carcinomatosis 107Lymphoma 95Neuroma, Acoustic 82Diffuse Intrinsic Pontine Glioma 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Head and Neck Neoplasms 79Ovarian Neoplasms 73Lymphoma, Follicular 73Pheochromocytoma 71Paraganglioma 68

Interventions

fludarabine 1Leukapheresis 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cytokine Release Syndrome × CNS × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡